



## ASSESSMENT OF HEMODYNAMIC RESPONSE MODULATION DURING EXTUBATION USING INTRAVENOUS MAGNESIUM SULFATE: A PROSPECTIVE COMPARATIVE STUDY

**Dr. Sai Janani K<sup>1\*</sup>, Dr. Befin K<sup>2</sup>, Dr. Maheswari R<sup>3</sup>**

<sup>1\*</sup>Junior Resident, Department of Emergency Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekaram, Kanyakumari.

<sup>2</sup>Associate Professor, Department of Emergency Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekaram, Kanyakumari.

<sup>3</sup>Professor and Head, Department of Emergency Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekaram, Kanyakumari.

**Corresponding Author:** Dr. Sai Janani K

Junior Resident, Department of Emergency Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekaram, Kanyakumari.

### ABSTRACT

**Background:** Extubation is associated with significant hemodynamic stress responses due to sympathetic stimulation, which may be harmful in susceptible patients. Magnesium sulfate, owing to its vasodilatory and sympatholytic properties, may attenuate these responses.

**Aim:** To evaluate the effectiveness of intravenous magnesium sulfate in attenuating hemodynamic responses during extubation.

**Methods:** This prospective, randomized comparative study was conducted on 60 patients (ASA I–II), aged 20–50 years, undergoing extubation in emergency medicine department and critical care ICU at Sree Mookambika College of Medical Sciences. Patients were divided into two groups: Group A received magnesium sulfate (30 mg/kg in 100 ml normal saline), and Group B received 100 ml normal saline. Hemodynamic parameters including heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure were recorded at baseline, during extubation, and up to 15 minutes post-extubation. Extubation quality, sedation score, and adverse effects were also assessed.

**Results:** Baseline demographic characteristics were comparable between the groups ( $p > 0.05$ ). From 2 minutes onwards and up to 15 minutes post-extubation, heart rate and blood pressure parameters (SBP, DBP, MAP) were significantly lower in the magnesium sulfate group compared to the control group ( $p < 0.05$ ). Extubation quality was better in Group A, with 83.3% of patients having favorable scores compared to 33.3% in Group B ( $p < 0.05$ ). Sedation scores were higher in the control group, while adverse effects were minimal and comparable between groups.

**Conclusion:** Magnesium sulfate at a dose of 30 mg/kg effectively attenuates hemodynamic responses to extubation, improves extubation quality, and has a favorable safety profile, making it a useful adjunct in anesthetic practice.

**Keywords:** Magnesium Sulfate, Extubation, Hemodynamic Response, General Anesthesia, Blood Pressure, Heart Rate.

### INTRODUCTION

Endotracheal extubation is frequently associated with significant hemodynamic alterations due to reflex sympathetic stimulation triggered by mechanical irritation of the epipharyngeal and laryngopharyngeal structures. This stimulation leads to a surge in catecholamine release, resulting in tachycardia, hypertension, and, in some cases, cardiac arrhythmias (1–3). Although these responses are usually transient and self-limiting, they may pose serious risks in patients with pre-existing cardiovascular or cerebrovascular conditions such as hypertension, coronary artery disease, and intracranial pathology.

In such patients, even short-lived increases in heart rate and blood pressure can precipitate myocardial ischemia, left ventricular failure, or cerebrovascular accidents.

Attenuation of the hemodynamic response during extubation has therefore become an important aspect of anesthetic management. Various pharmacological agents and techniques have been studied for this purpose, aiming to provide a smooth and stable emergence from anesthesia. Among these, opioids (narcotics) are widely used due to their ability to blunt sympathetic responses, though they may cause respiratory depression. Local anesthetics, administered intravenously or topically, reduce airway reflexes and minimize stimulation. Alpha-2 adrenergic agonists, such as clonidine and dexmedetomidine, have gained popularity for their sedative and sympatholytic properties. Calcium



www.ajmrhs.com  
eISSN: 2583-7761

Date of Received: 29-05-2026  
Date Acceptance: 07-06-2026  
Date of Publication: 06-07-2026

channel blockers and beta-adrenergic blockers are also employed to control tachycardia and hypertension associated with extubation (4–7).

In recent years, magnesium sulfate has emerged as a potential agent for attenuating extubation responses due to its ability to inhibit catecholamine release and block calcium channels, thereby providing both vasodilatory and antiarrhythmic effects. Its role in modulating hemodynamic responses during extubation is being increasingly explored. Therefore, the present study aims to evaluate the effectiveness of intravenous magnesium sulfate infusion in attenuating the hemodynamic response during extubation and to assess its potential benefits in improving perioperative cardiovascular stability.

#### Aim

To evaluate the effectiveness of intravenous magnesium sulfate infusion in attenuating the hemodynamic response during endotracheal extubation.

#### Objectives

To assess changes in heart rate during and after extubation following administration of intravenous magnesium sulfate.

### METHODOLOGY

The present study was a single-center, hospital-based, prospective comparative study conducted among 60 patients over a period of one year from January 2021 to December 2022 at the extubation in emergency medicine department and critical care ICU at Sree Mookambika College of Medical Sciences, Sree Mookambika College of Medical Sciences, Kulasekharam, Tamil Nadu, India. The study was approved by the Institutional Ethics Committee, and written informed consent was obtained from all participants.

Patients with hypertension, uncontrolled diabetes mellitus, cardiopulmonary diseases, hepatic

dysfunction, renal dysfunction, psychiatric illness, pregnant or lactating women, those undergoing emergency procedures, and patients requiring postoperative ventilation were excluded.

Patients were randomly divided into two groups of 30 each:

Group A (Study group): Received intravenous magnesium sulfate 30 mg/kg diluted in 100 ml normal saline over 10 minutes

Group B (Control group): Received 100 ml normal saline intravenously over 10 minutes

Upon arrival in the operating room, baseline parameters including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), respiratory rate (RR), ECG, and oxygen saturation (SpO<sub>2</sub>) were recorded. patients were extubated after meeting standard extubation criteria. Hemodynamic parameters including heart rate, systolic blood pressure, and diastolic blood pressure were recorded at the time of drug administration and at 1, 3, 5, 10, and 15 minutes following extubation.

Data were entered into Microsoft Excel and analyzed using Statistical Package for the Social Sciences (SPSS) software (version XX). Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages.

Comparison between the two groups was performed using: Independent Student's t-test for continuous variables Chi-square test or Fisher's exact test for categorical variables

Repeated measures within the groups (hemodynamic parameters over time) were analyzed using repeated measures ANOVA, followed by post hoc analysis where applicable. A p-value of <0.05 was considered statistically significant.

### RESULT

Table1: Comparison of Demographic Profile in Two Groups

| Parameters     | GroupA(MgSO <sub>4</sub> ) N=30 | GroupB(control) N=30 | p      |
|----------------|---------------------------------|----------------------|--------|
| Age(years)     | 37.62 ± 15.31                   | 33±6.93              | 0.1376 |
| Height(cm)     | 155.68 ± 7.14                   | 154.79±6.25          | 0.6260 |
| Weight(kg)     | 59.87 ± 12.73                   | 62.43±6.84           | 0.3359 |
| SexM :F        | 16, 14                          | 10,20                | 0.1930 |
| ASA grade I/II | 13, 17                          | 18,12                | 0.3032 |

Both the groups were comparable for baseline demographic characteristics and ASA grade. (p>0.05) (Table 1)

Table2: Comparison of Heart Rate Response in Two Groups

| Timings  | Group A Mean±SD | GroupB Mean±SD | p value |
|----------|-----------------|----------------|---------|
| Baseline | 84.13 ± 7.68    | 84±8.990       | 0.9522  |
| 1 min    | 83.07 ± 7.5     | 84.60±8.017    | 0.4484  |
| 2 min    | 81.37 ± 6.95    | 86.07±8.229    | 0.02012 |
| 3 min    | 79.53 ± 7.2     | 86.47±7.977    | 0.00081 |

|            |              |             |         |
|------------|--------------|-------------|---------|
| Extubation | 79.07 ± 6.25 | 86.60±7.596 | 0.00009 |
| 1 min      | 83.2 ± 6.12  | 92.67±8.458 | <0.0001 |
| 3 min      | 84.2 ± 6.48  | 94.20±7.416 | <0.0001 |
| 5 min      | 82.4 ± 6.33  | 92.87±6.511 | <0.0001 |
| 10 min     | 80.6 ± 6.28  | 91.47±6.642 | <0.0001 |
| 15 min     | 79.47 ± 5.53 | 89.67±6.687 | <0.0001 |

The heart rate at baseline and at one min was comparable in two groups ( $p>0.05$ ). From two min onwards and at extubation and further till 15 min, the heart rate was consistently more in control group

(group B) compared to study group (group A) and this was found to be statistically significant ( $p<0.05$ ). (Table 2)

Table3: Comparison of Systolic Blood Pressure (SBP) Response in Two Groups

| Timings    | GroupA Mean±SD | GroupB Mean±SD | p value |
|------------|----------------|----------------|---------|
| Baseline   | 121.53 ± 6.34  |                | 0.9396  |
| 1 min      | 120.4 ± 5.57   | 120.80±5.933   | 0.7881  |
| 2 min      | 117.73±5.91    | 120.67±6.133   | 0.05609 |
| 3 min      | 116.47±5.06    | 121.33±5.616   | 0.0008  |
| Extubation | 115.6±4.34     | 121.13±5.625   | <0.0001 |
| 1 min      | 119.6±5.54     | 126.13±5.823   | <0.0001 |
| 3 min      | 119.33±5.52    | 125.40±5.334   | <0.0001 |
| 5 min      | 117.27±5.05    | 123.12±5.575   | <0.0001 |
| 10 min     | 116.2± 5.1     | 121.20±4.999   | <0.0001 |
| 15 min     | 115.13±4.83    | 119.73±5.626   | <0.0001 |

The SBP at base line, at one and two min was comparable in two groups ( $p>0.05$ ). At three min, then at extubation and thereafter till 15 min, it was

more in the group B patients compared to group A patients and this difference was found to be statistically significant ( $p<0.05$ ). (Table3)

Table4: Comparison of diastolic blood pressure (DBP) Response

| Timings    | Group A Mean±SD | GroupB Mean±SD | p value |
|------------|-----------------|----------------|---------|
| Baseline   | 71.33 ± 3.34    | 70.00±19.518   | 0.7140  |
| 1 min      | 74.11±3.97      | 74.20±4.437    | 0.9335  |
| 2 min      | 72.67 ± 4.25    | 73.53±4.091    | 0.1374  |
| 3 min      | 75.53± 5.11     | 76.60±3.450    | 0.3480  |
| Extubation | 70.73 ± 3.62    | 75.73±3.704    | <0.0001 |
| 1 min      | 73.13 ± 3.7     | 79.27±3.769    | <0.0001 |
| 3 min      | 72.27 ± 4.92    | 79.13±3.589    | <0.0001 |
| 5 min      | 70.73 ± 3.51    | 77.80±3.690    | <0.0001 |
| 10 min     | 70.27 ± 3.27    | 76.33±3.407    | <0.0001 |
| 15 min     | 70.33 ± 3.53    | 75.53±3.431    | <0.0001 |

The DBP at baseline and till three min was not significantly different in two groups ( $p>0.05$ ). But from extubation onwards till 15 min, it was

consistently more in patients belonging to group B compared to patients from group A and it was also statistically significant ( $p<0.05$ ). (Table 4)

Table5: Comparison of Mean Arterial Pressure (MAP) Response

| Timings    | GroupA Mean±SD | GroupA Mean±SD | P value |
|------------|----------------|----------------|---------|
| Baseline   | 90.71±4.15     | 89.97±3.728    | 0.4719  |
| 1 min      | 89.33±3.84     | 90.30±3.436    | 0.3046  |
| 3 min      | 87.87±4.36     | 90.53±3.481    | 0.0121  |
| 5 min      | 86.37±3.45     | 91.43±2.956    | <0.0001 |
| Extubation | 85.63±3.25     | 90.93±3.226    | <0.0001 |
| 1 min      | 88.27±3.91     | 94.77±3.319    | <0.0001 |
| 3 min      | 88.34±4.13     | 94.57±2.881    | <0.0001 |
| 5 min      | 86.37±3.31     | 93.00±3.434    | <0.0001 |

|        |            |             |         |
|--------|------------|-------------|---------|
| 10 min | 85.81±3.19 | 91.37±3.135 | <0.0001 |
| 15 min | 85.13±3.36 | 90.23±3.036 | <0.0001 |

The MAP at base line, and at one min was found to be similar in two groups ( $p>0.05$ ). At three and five min from base line as well as at extubation and till 15

min further, it was significantly more in patients of group B compared to patients of group A ( $p<0.05$ ). (Table 5)

Table6: Comparison of Extubation Score

| Extubationscore | GroupA( 30) |      | GroupB (30) |      | Pvalue   |
|-----------------|-------------|------|-------------|------|----------|
|                 | No.         | %    | No.         | %    |          |
| 1 &2            | 25          | 83.3 | 10          | 33.3 | 0.000246 |
| 3               | 5           | 16.7 | 20          | 66.7 |          |

There were 83.3% of patients in group A with extubation score of one and two compared to only 33.3% in group B. Those with extubation score of three

were significantly less in group A compared to group B. ( $p<0.05$ ) There were no cases having extubation score of more than three. (Table 6)

Table7: Comparison of Sedation Score

| Ramsay sedationscore | GroupA(30) |     | GroupB(30) |       | P value |
|----------------------|------------|-----|------------|-------|---------|
|                      | No.        | %   | Number     | %     |         |
| 1                    | 9          | 30% | 2          | 6.6%  | 0.0453  |
| 2                    | 21         | 70% | 28         | 93.3% |         |

Patients with Ramsay sedation score of two were significantly more in group B (93.3%) compared to group A (70%) ( $P<0.05$ ). (Table 7)

Table8: Comparison of Side effects

| Side effects | GroupA(30) |      | GroupB(30) |      | P value |
|--------------|------------|------|------------|------|---------|
|              | No.        | %    | Number     | %    |         |
| Present      | 1          | 3.3  | 4          | 13.3 | 0.3533  |
| Absent       | 29         | 96.7 | 26         | 86.7 |         |

One case of vomiting in group A; two cases of tachycardia and two cases of vomiting in group B. There was only one case with side effects in group A compared to four cases in group B, but the difference was not found to be statistically significant. (Table 8)

## DISCUSSION

The present study evaluated the effect of intravenous magnesium sulfate ( $MgSO_4$ ) on attenuation of hemodynamic responses during extubation and demonstrated that  $MgSO_4$  significantly reduces cardiovascular responses compared to placebo, particularly in the post-extubation period. Both groups were comparable with respect to demographic variables such as age, sex, height, weight, and ASA grade, with no statistically significant differences ( $p > 0.05$ ), thereby ensuring that the observed hemodynamic variations were attributable to the intervention rather than confounding factors. Heart rate remained similar between groups at baseline and at 1 minute; however, from 2 minutes onward, including during extubation and up to 15 minutes post-extubation, it was significantly higher in the control group, indicating effective suppression of sympathetic stimulation by magnesium sulfate. These findings

are consistent with studies by Nooraei N et al. and Shukla S et al., which demonstrated attenuation of heart rate responses with magnesium sulfate. Systolic blood pressure (SBP) was comparable initially but became significantly elevated in the control group from 3 minutes onward and during extubation, suggesting that magnesium sulfate effectively blunts the pressor response, likely due to its vasodilatory effects mediated through calcium channel antagonism and inhibition of catecholamine release, as supported by Zhang J et al. Similarly, diastolic blood pressure (DBP) did not differ significantly until 3 minutes but was significantly higher in the control group thereafter, reflecting reduced systemic vascular resistance in the magnesium group.

Mean arterial pressure (MAP) followed a similar pattern, with significantly higher values in the control group during extubation and the post-extubation period, further confirming the role of magnesium sulfate in maintaining hemodynamic stability. The quality of extubation was also superior in the magnesium group, with a higher proportion of patients demonstrating smoother extubation profiles, consistent with previous findings. Sedation scores revealed that magnesium sulfate did not

produce excessive sedation, maintaining adequate consciousness while ensuring hemodynamic control.

The incidence of adverse effects was minimal and comparable between groups, indicating a favorable safety profile. Overall, the study confirms that intravenous magnesium sulfate at a dose of 30 mg/kg is effective and safe in attenuating hemodynamic responses to extubation. Although other agents like dexmedetomidine and fentanyl may provide stronger attenuation, magnesium sulfate remains a cost-effective and practical alternative, particularly in resource-limited settings.

### CONCLUSION

Intravenous magnesium sulfate at a dose of 30 mg/kg effectively attenuates the hemodynamic responses associated with extubation, as evidenced by significantly lower heart rate, systolic, diastolic, and mean arterial pressures compared to the control group. It also improves the quality of extubation without causing significant adverse effects. Magnesium sulfate is a safe, effective, and economical agent for achieving hemodynamic stability during extubation and can be considered a useful adjunct in routine anesthetic practice.

### REFERENCES

1. King BD, Harris LC, Greifenstein FE, Elder JD, Dripps RD. Reflex circulatory responses to direct laryngoscopy and tracheal intubation. *Anesthesiology*. 1951;12(5):556–66.
2. Forbes AM, Dally FG. Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. *Br J Anaesth*. 1970;42(7):618–24.
3. Derbyshire DR, Chmielewski A, Fell D, Vater M, Achola K, Smith G. Plasma catecholamine responses to tracheal intubation. *Br J Anaesth*. 1983;55(9):855–60.
4. Bidwai AV, Bidwai VA, Rogers CR, Stanley TH. Blood pressure and pulse rate responses to endotracheal extubation with and without prior injection of lidocaine. *Anesthesiology*. 1979;51(2):171–3.
5. Mikawa K, Nishina K, Maekawa N, Obara H. Attenuation of cardiovascular responses to tracheal extubation: comparison of verapamil, diltiazem, and nicardipine. *Anesth Analg*. 1996;82(6):1205–10.
6. Guler G, Akin A, Tosun Z, Eskitascioglu E, Mizrak A, Boyaci A. Single-dose dexmedetomidine attenuates airway and circulatory reflexes during extubation. *Acta Anaesthesiol Scand*. 2005;49(8):1088–91.
7. Kovac AL. Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. *J Clin Anesth*. 1996;8(1):63–79.
8. Nooraei N, Dehkordi ME, Radpay B, et al. Comparison of magnesium sulfate and lidocaine on hemodynamic responses to laryngoscopy and intubation: A randomized clinical trial. *Anesth Pain Med*. 2013;3(2):251–256.
9. Shukla S, Singh A, Pandey R, et al. Comparison of dexmedetomidine, fentanyl, and magnesium sulfate on attenuation of hemodynamic response to laryngoscopy and intubation. *J Anaesthesiol Clin Pharmacol*. 2017;33(1):57–62.
10. Zhang J, Wang X, Li J, et al. Effect of magnesium sulfate on hemodynamic responses to tracheal intubation: A meta-analysis of randomized controlled trials. *J Clin Anesth*. 2016;34:27–36.

**How to cite this article:** Dr Befin K, Dr Sai Janani K, EVALUATION OF BILEVEL NONINVASIVE VENTILATION AGAINST CONVENTIONAL OXYGEN THERAPY IN THE TREATMENT OF ACUTE CARDIOGENIC PULMONARY EDEMA, *Asian J. Med. Res. Health Sci.*, 2026; 4 (2): 1722-1726.

**Source of Support:** Nil, Conflicts of Interest: None declared.